Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)

Paul J Bröckelmann, MD, Horst Müller, PhD, Olivier Casasnovas, MD, Martin Hutchings, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Craig Moskowitz, MD, Andreas Engert, MD

Blood (2015) 126 (23): 1978.

https://doi.org/10.1182/blood.V126.23.1978.1978

Published: 2015

Journal Articles

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Eric Van Den Neste, MD PhD, Norbert Schmitz, MD, Nicolas Mounier, MD PhD, Devinder Gill, MB FRCPath FRACP FRCPA, Marek Trneny, MD, PhD, Prof., Noel Milpied, John A. Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, Ulrich Dührsen, David Ma, MD, Josette Briere, Catherine Thieblemont, Gilles A. Salles, MD PhD, Craig Moskowitz, MD, Bertran Glass, Christian Gisselbrecht

Blood (2015) 126 (23): 517.

https://doi.org/10.1182/blood.V126.23.517.517

Published: 2015

Journal Articles

Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma

Craig Moskowitz, MD, Paul A Hamlin, Jr., Jocelyn Maragulia, Jessica Meikle, Andrew D Zelenetz, MD

Blood (2010) 116 (21): 420.

https://doi.org/10.1182/blood.V116.21.420.420

Published: 2010

Journal Articles

Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma.

Basciano A. Basciano, MD, Craig Moskowitz, MD, Andrew D. Zelenetz, MD, PhD

Blood (2009) 114 (22): 1558.

https://doi.org/10.1182/blood.V114.22.1558.1558

Published: 2009

Journal Articles

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Alison J. Moskowitz, MD, Stephen D. Nimer, Andrew D. Zelenetz, MD, PhD, Tarun Kewalramani, MD, Jill M Vanak, ACNP, Jocelyn c Maragulia, Joachim Yahalom, MD, Craig Moskowitz, MD

Blood (2008) 112 (11): 776.

https://doi.org/10.1182/blood.V112.11.776.776

Published: 2008

Journal Articles

Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome

Andrew D Zelenetz, MD, PhD, Craig Moskowitz, MD, Jocelyn Maragulia, Carol S. Portlock, Julie Teruya-Feldstein

Blood (2008) 112 (11): 3759.

https://doi.org/10.1182/blood.V112.11.3759.3759

Published: 2008

Journal Articles

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

Christian Gisselbrecht, MD, Norbert Schmitz, MD, Nicolas Mounier, MD, PhD, David Ma, MD, Marek Trneny, MD, Hans Hagberg, MD, David C. Linch, MD, Ofer Shpilberg, MD, Nicolas Ketterer, MD, Bertram Glass, MD, Andre Bosly, MD, Devinder Gill, MD, Philippe Gaulard, MD, Craig Moskowitz, MD

Blood (2007) 110 (11): 517.

https://doi.org/10.1182/blood.V110.11.517.517

Published: 2007

Journal Articles

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

Trudy N. Small, MD, Robert D. Rice, RN, Emily McCullagh, Ariela Noy, Tanya Trippett, Steven M. Horwitz, Andrew D. Zelenetz, Craig Moskowitz

Blood (2007) 110 (11): 603.

https://doi.org/10.1182/blood.V110.11.603.603

Published: 2007

Journal Articles

Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

Craig Moskowitz, MD, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Ariela Noy, MD, Owen A. O’Connor, MD,PhD, M. Lia Palomba, MD, Carol S. Portlock, MD, David J. Straus, MD, Simone Chennin-Lessac, Alandra Weaver, Julie Teruva-Feldstein, MD, Heiko Schoder, MD, Andrew D. Zelenetz, MD,PhD

Blood (2006) 108 (11): 532.

https://doi.org/10.1182/blood.V108.11.532.532

Published: 2006

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

Journal Articles

Is it time to stop treating subsets of DLBCL with R-CHOP?

Craig Moskowitz

Blood (2006) 107 (11): 4197–4198.

https://doi.org/10.1182/blood-2006-03-008995

Published: 2006

Journal Articles

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Steven Horwitz, MD, Craig Moskowitz, MD, Tarun Kewalramani, MD, Paul Hamlin, MD, David Straus, MD, Owen O’Connor, MD, PhD, Ariela Noy, MD, Carol Portlock, MD, Stephen Nimer, MD, PhD, M. Lia Palomba, MD, PhD, Andrew Zelenetz, MD, PhD

Blood (2005) 106 (11): 2679.

https://doi.org/10.1182/blood.V106.11.2679.2679

Published: 2005

Journal Articles

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

David J. Straus, Carol S. Portlock, Jing Qin, Jane Myers, Andrew D. Zelenetz, Craig Moskowitz, Ariela Noy, André Goy, Joachim Yahalom

Blood (2004) 104 (12): 3483–3489.

https://doi.org/10.1182/blood-2004-04-1311

Published: 2004

Journal Articles

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Owen O’Connor, MD, PhD, John Wright, Craig Moskowitz, MD, Barbara MacGregor-Cortelli, RN, David Straus, MD, Andrew Evans, MD, Jane Winter, MD, Omer Koc, MD, Nancy Horvath, RN, Susan Blumel, MD, Julie Vose, MD, David Schenkein, MD, Andrew Zelenetz, MD

Blood (2004) 104 (11): 607.

https://doi.org/10.1182/blood.V104.11.607.607

Published: 2004

NARROW

Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL)

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Sequential Dose-Dense RCHOP Followed by ICE Consolidation (MSKCC protocol 01–142) without Radiotherapy for Patients with Primary Mediastinal Large B Cell Lymphoma

Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma.

Pre-Transplant Evaluation with Both CT and PET Following Second-Line Therapy Is Essential for Predicting Outcome in Patients with Transplant- Eligible Relapsed and Primary Refractory Hodgkin Lymphoma

Sequential Chemotherapy Followed by High Dose Therapy and Autologous Stem Cell Rescue for Mantle Cell Lymphoma: Impact of MIB-1 on Outcome

R-ICE Versus R-DHAP in Relapsed Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Followed by Stem Cell Transplantation and Maintenance Treatment with Rituximab or Not: First Interim Analysis on 200 Patients. CORAL Study.

Vaccine Efficacy Following Autologous Peripheral Blood Stem Cell Transplant for Lymphoma.

Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Is it time to stop treating subsets of DLBCL with R-CHOP?

Second-Line Therapy with ICE Followed by High Dose Therapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Lymphomas: Minimal Benefit When Analyzed by Intent To Treat.

Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease

A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only